Treatment response to cyclophosphamide, rituximab, and bortezomib in chronic immune-mediated sensorimotor neuropathies: a retrospective cohort study:
2021
Background:Up to 20% of patients with chronic immune-mediated sensorimotor neuropathies (CIN) do not respond adequately to first-line therapies. However, studies on further treatment are scarce.Met...
Keywords:
-
Correction
-
Source
-
Cite
-
Save
44
References
4
Citations
NaN
KQI